BTK(C481S)-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

PURPOSE: Therapeutic targeting of Bruton tyrosine kinase (BTK) with ibrutinib in chronic lymphocytic leukemia has led to a paradigm shift in therapy, and relapse has been uncommon with current follow-up. Acquired mutations in BTK and PLCG2 can cause relapse, but data regarding the prevalence and nat...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Main Authors: Woyach, Jennifer A., Ruppert, Amy S., Guinn, Daphne, Lehman, Amy, Blachly, James S., Lozanski, Arletta, Heerema, Nyla A., Zhao, Weiqiang, Coleman, Joshua, Jones, Daniel, Abruzzo, Lynne, Gordon, Amber, Mantel, Rose, Smith, Lisa L., McWhorter, Samantha, Davis, Melanie, Doong, Tzyy-Jye, Ny, Fan, Lucas, Margaret, Chase, Weihong, Jones, Jeffrey A., Flynn, Joseph M., Maddocks, Kami, Rogers, Kerry, Jaglowski, Samantha, Andritsos, Leslie A., Awan, Farrukh T., Blum, Kristie A., Grever, Michael R., Lozanski, Gerard, Johnson, Amy J., Byrd, John C.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2017
Assuntos:
ORIGINAL REPORTS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5455463/
https://ncbi.nlm.nih.gov/pubmed/28418267
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.70.2282
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares